MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
JANX Janux Therapeutics
- 56.830
- +0.080+0.14%
Close Dec 20 16:00 ET
- 56.830
- 0.0000.00%
Post 16:11 ET
3.33BMarket Cap-48.57P/E (TTM)
59.720High55.630Low1.25MVolume56.370Open56.750Pre Close71.73MTurnover2.83%Turnover RatioLossP/E (Static)58.63MShares71.71052wk High5.08P/B2.51BFloat Cap7.79052wk Low--Dividend TTM44.20MShs Float71.710Historical High--Div YieldTTM7.21%Amplitude5.650Historical Low57.297Avg Price1Lot Size
About Janux Therapeutics Company
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Company Profile
SymbolJANX
Company NameJanux Therapeutics
Listing DateJun 11, 2021
Issue Price17.00
Founded2017
CEODr. David Campbell, PhD
MarketNASDAQ
Employees64
Fiscal Year Ends12-31
Address11099 North Torrey Pines Park,Suite 290
CityLa Jolla
ProvinceCalifornia
CountryUnited States of America
Zip Code92037
Phone1-858-750-4700
Websitehttp://www.januxrx.com
Company Executives
- Name
- Position
- Salary
- Dr. David Campbell, PhD
- Director, President and Chief Executive Officer
- 4.19M
- Tighe Reardon
- Acting Chief Financial Officer and Principal Accounting Officer
- --
- Andy Meyer
- Chief Business Officer
- --
- Charles M. Winter
- Chief Technical Officer
- 1.61M
- Dr. Tommy DiRaimondo, PhD
- Chief Scientific Officer
- --
- Dr. Byron Robinson, PhD
- Chief Strategy Officer
- 1.74M
- Dr. Ronald W. Barrett, PhD
- Chairman of the Board
- 162.69K
- Natasha A. Hernday
- Director
- --
- Dr. Sheila Gujrathi, M.D.
- Director
- 158.01K
- Eric L. Dobmeier
- Director
- --
- Winston Kung, M.B.A.
- Independent Director
- 164.77K
- Dr. Jake Sin, PhD
- Independent Director
- 172.07K
- Alana B. McNulty
- Independent Director
- 166.57K
- Vickie L. Capps
- Independent Director
- 173.01K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.